Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes

患有糖尿病前期的墨西哥裔美国人对 GLP-1 反应的药物遗传学

基本信息

项目摘要

ABSTRACT This clinical trial will uncover new mechanisms of inter-individual responses to endogenous and exogenous glucagon-like peptide-1 (GLP-1) in Hispanics/Latinos (H/Ls) with prediabetes. The results move the management of prediabetes, type 2 diabetes mellitus (T2DM), and relevant metabolic diseases to a more individualized approach in an understudied and at-risk population. Few options exist for prediabetes treatment, and the current pharmaceutical management of T2DM does not predict drug treatment failures, nor differences in individual treatment responses and adverse effects. A precise, genetics-based approach will provide superior therapeutic management for patients. GLP-1-based therapies reduce blood glucose, promote weight loss, decrease cardiovascular events, and improve renal function. Prior genetic studies, most done in Caucasians, identified associations between genetic variants and decreased GLP-1-induced insulin secretion, in an effort to guide individualized treatment. However, these associations do not provide a clear mechanistic relationship between genotype and phenotype. Transcriptomic analyses will uncover many of these mechanisms. Here, we propose to 1) test the association of single nucleotide polymorphisms (SNPs) that regulate expression (eQTLs) of 11 candidate genes in a range of relevant metabolic tissues with differential GLP-1 response, 2) perform RNA sequencing before and after treatment to identify eQTLs in blood that predict response to GLP-1 therapy and develop risk-based prediction models in H/Ls, and 3) determine the effects of genetic regulation of candidate genes and newly discovered eQTLs phenome-wide in a large existing biobank, BioVU. For aims 1 and 2, responses will be measured in 300 study subjects with prediabetes recruited from an established Mexican- American cohort via the oral minimal model method, before and after GLP-1 therapy, quantifying GLP-1 hormone efficacy and GLP-1-induced pancreatic beta cell insulin release and peripheral insulin sensitivity. Procedures include serial measurements of plasma glucose, insulin, C-peptide, and GLP-1, and peripheral blood collection for RNA sequencing. Our central hypotheses are: (1) metabolic tissue-based eQTLs of GLP-1- associated genes will be associated with physiological response to endogenous and exogenous GLP-1, (2) identification of eQTLs associated with GLP-1 treatment-induced changes in whole blood will identify new gene targets, and (3) this data will lead to the creation of eQTL-based prediction models for related diseases. The study is innovative because it uses a novel combination of eQTL analysis and oral minimal model to assess GLP-1 response, examines a population highly underrepresented in pharmacogenomic studies, and utilizes novel statistical methods and applications to study gene expression. The significance of this newly acquired mechanistic information will ultimately guide precision therapeutic regimens for diabetes prevention and treatment, weight loss, cardiovascular risk reduction, and related metabolic complications in an understudied population.
摘要 这项临床试验将揭示内源性和外源性的个体间反应的新机制 胰高血糖素样肽-1(GLP-1)在西班牙裔/拉丁裔(H/Ls)糖尿病前期患者中的作用。结果将 糖尿病前期、2型糖尿病(T2 DM)和相关代谢疾病的管理, 个体化的方法在研究不足和高危人群。糖尿病前期治疗的选择很少, 目前的T2 DM药物管理不能预测药物治疗失败, 个体治疗反应和副作用。一个精确的,基于遗传学的方法将提供上级 患者的治疗管理。基于GLP-1的治疗降低血糖,促进体重减轻, 减少心血管事件,改善肾功能。先前的遗传学研究,大多数是在高加索人中进行的, 确定了遗传变异与GLP-1诱导的胰岛素分泌减少之间的关联, 指导个体化治疗。然而,这些关联并没有提供一个明确的机械关系 基因型和表现型之间的区别转录组学分析将揭示许多这些机制。这里我们 建议1)测试调节表达的单核苷酸多态性(SNP)(eQTL)的关联 在具有差异GLP-1应答的一系列相关代谢组织中的11个候选基因中,2)进行RNA转录, 治疗前后测序,以鉴定血液中预测GLP-1治疗应答的eQTL, 建立基于风险的H/L预测模型,3)确定候选基因的遗传调控效应 基因和新发现的eQTL表型广泛的一个大型现有的生物库,BioVU。对于目标1和2, 将在300名患有前驱糖尿病的研究受试者中测量反应,这些受试者是从一个已建立的墨西哥- 通过口服最小模型方法,在GLP-1治疗前后定量GLP-1的美国队列 激素功效和GLP-1诱导胰腺β细胞胰岛素释放和外周胰岛素敏感性。 程序包括连续测量血糖、胰岛素、C肽和GLP-1以及外周血 收集RNA测序。我们的中心假设是:(1)GLP-1的代谢组织eQTL- 相关基因将与对内源性和外源性GLP-1的生理反应相关, (2)与GLP-1处理诱导的全血变化相关的eQTL的鉴定将鉴定新的 基因靶点,以及(3)这些数据将导致创建基于eQTL的相关疾病预测模型。 这项研究是创新的,因为它使用了eQTL分析和口腔最小模型的新组合来评估 GLP-1应答,检查药物基因组学研究中代表性极低的人群,并利用 新的统计方法和应用研究基因表达。这个新获得的重要性 机械信息将最终指导糖尿病预防的精确治疗方案, 治疗、减肥、心血管风险降低和相关代谢并发症, 人口

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Absalon Dennis Gutierrez其他文献

Absalon Dennis Gutierrez的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Absalon Dennis Gutierrez', 18)}}的其他基金

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes
患有糖尿病前期的墨西哥裔美国人对 GLP-1 反应的药物遗传学
  • 批准号:
    10448426
  • 财政年份:
    2021
  • 资助金额:
    $ 69.49万
  • 项目类别:
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes
患有糖尿病前期的墨西哥裔美国人对 GLP-1 反应的药物遗传学
  • 批准号:
    10299488
  • 财政年份:
    2021
  • 资助金额:
    $ 69.49万
  • 项目类别:
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
GLP-1 疗法:IL-6 信号传导和脂肪组织重塑在代谢反应中的作用
  • 批准号:
    9808679
  • 财政年份:
    2019
  • 资助金额:
    $ 69.49万
  • 项目类别:
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
GLP-1 疗法:IL-6 信号传导和脂肪组织重塑在代谢反应中的作用
  • 批准号:
    10015259
  • 财政年份:
    2019
  • 资助金额:
    $ 69.49万
  • 项目类别:
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
GLP-1 疗法:IL-6 信号传导和脂肪组织重塑在代谢反应中的作用
  • 批准号:
    10264099
  • 财政年份:
    2019
  • 资助金额:
    $ 69.49万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 69.49万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 69.49万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了